{1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl}methanol | 639784-65-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: {1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl}methanol
• 英文别名: [2-methyl-5-(4-trifluoromethyl-phenyl)-2H-pyrazol-3-yl]-methanol；1-METHYL-3-(4-TRIFLUOROMETHYLPHENYL)-5-HYDROXYMETHYL-PYRAZOLE；(1-Methyl-3-(4-(trifluoromethyl)phenyl)-1H-pyrazol-5-YL)methanol；[2-methyl-5-[4-(trifluoromethyl)phenyl]pyrazol-3-yl]methanol
• CAS: 639784-65-9
• 化学式: C₁₂H₁₁F₃N₂O
• 分子量: 256.227
• InChiKey: QOFNWGFKSVNBTA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  {1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl}methanol 在 三溴化磷 作用下， 以 乙醚 为溶剂， 以85%的产率得到5-(bromomethyl)-1-methyl-3-[4-(trifluoromethyl)-phenyl]-1H-pyrazole
  参考文献：
  名称：

  Synthesis and Structure−activity Relationships of Antitubercular 2-Nitroimidazooxazines Bearing Heterocyclic Side Chains

  摘要：

  Recently described biphenyl analogues Of the antituberculosis drug PA-824 displayed improved potencies against M. tuberculosis but were poorly soluble. Heterobiaryl analogues of these, in which the first phenyl ring was replaced with various 5-membered ring heterocycles, were prepared with the aim of identifying potent new candidates with improved aqueous solubility. The compounds were constructed by coupling the chiral 2-nitroimidazooxazine alcohol with various halomethyl-substituted arylheterocycles, by cycloadditions to a propargyl ether derivative of this alcohol, or by Suzuki couplings on haloheterocyclic methyl ether derivatives. The arylheterocyclic compounds were all more hydrophilic than their corresponding biphenyl analogues, and several showed solubility improvements. 1-Methylpyrazole, 1,3-linked-pyrazole, 2,4-linked-triazole, and tetrazole analogues had 3- to 7-fold higher MIC potencies against replicating M. tb than predicted by their lipophilicities. Two pyrazole analogues were >10-fold more efficacious than the parent drug in a mouse model of acute M. tb infection, and one displayed a 2-fold higher solubility.

  DOI：

  10.1021/jm901378u
• 作为产物：
  描述：

  1-methyl-5-[(tetrahydro-2H-pyran-2-yloxy)methyl]-3-[4-(trifluoromethyl)phenyl]-1H-pyrazole 在 盐酸 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以75%的产率得到{1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl}methanol
  参考文献：
  名称：

  Synthesis and Structure−activity Relationships of Antitubercular 2-Nitroimidazooxazines Bearing Heterocyclic Side Chains

  摘要：

  Recently described biphenyl analogues Of the antituberculosis drug PA-824 displayed improved potencies against M. tuberculosis but were poorly soluble. Heterobiaryl analogues of these, in which the first phenyl ring was replaced with various 5-membered ring heterocycles, were prepared with the aim of identifying potent new candidates with improved aqueous solubility. The compounds were constructed by coupling the chiral 2-nitroimidazooxazine alcohol with various halomethyl-substituted arylheterocycles, by cycloadditions to a propargyl ether derivative of this alcohol, or by Suzuki couplings on haloheterocyclic methyl ether derivatives. The arylheterocyclic compounds were all more hydrophilic than their corresponding biphenyl analogues, and several showed solubility improvements. 1-Methylpyrazole, 1,3-linked-pyrazole, 2,4-linked-triazole, and tetrazole analogues had 3- to 7-fold higher MIC potencies against replicating M. tb than predicted by their lipophilicities. Two pyrazole analogues were >10-fold more efficacious than the parent drug in a mouse model of acute M. tb infection, and one displayed a 2-fold higher solubility.

  DOI：

  10.1021/jm901378u

文献信息

• Indolyl derivatives
  申请人：Ackermann Jean

  公开号：US20050203160A1

  公开（公告）日：2005-09-15

  This invention relates to compounds of the formula I: wherein one of R 6 , R 7 and R 8 is and R 1 to R 15 and n are as defined in the description, and all enantiomers and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPAR δ and/or PPARα agonists.

  这项发明涉及式I的化合物：其中R6、R7和R8中的一个是R1至R15和n如描述中所定义的，以及其所有对映体和药用盐和/或酯。该发明还涉及含有这种化合物的药物组合物，以及用于治疗和/或预防由PPAR δ和/或PPARα激动剂调节的疾病的方法。
• Phenyloxyalkanonic acid derivatives as hppar activators
  申请人：Dodic Nerina

  公开号：US20050222424A1

  公开（公告）日：2005-10-06

  A compound of formula (I) or a pharmaceutically acceptable salt, solvate, or hydrolysable ester thereof, wherein:

  化合物公式(I)或其药学上可接受的盐、溶剂化物或可水解酯，其中：
• Heterocyclic GPR40 Modulators
  申请人：Beck Hilary

  公开号：US20080090840A1

  公开（公告）日：2008-04-17

  The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

  本发明提供了一些化合物，例如用于治疗受试者的代谢紊乱。此类化合物具有一般式I，其中变量的定义在此提供。本发明还提供了包含这些化合物的组合物以及使用这些化合物制备药物和治疗代谢紊乱（例如II型糖尿病）的方法。
• HETEROCYCLIC GPR40 MODULATORS
  申请人：Beck Hilary

  公开号：US20100075974A1

  公开（公告）日：2010-03-25

  The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

  本发明提供了一些化合物，例如，用于治疗受试者的代谢紊乱。这些化合物具有一般式I：其中变量的定义在此提供。本发明还提供了包括这些化合物的组合物，以及使用这些化合物制备药物和治疗代谢紊乱的方法，例如类型II糖尿病。
• [EN] PHENYLOXYALKANONIC ACID DERIVATIVES AS HPPAR ACTIVATORS<br/>[FR] COMPOSES CHIMIQUES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2004000785A3

  公开（公告）日：2004-10-14